Human Immunodeficiency Virus-Infected Adolescents: The First 50 Patients in a New York City Program

PEDIATRICS ◽  
1993 ◽  
Vol 91 (4) ◽  
pp. 730-735 ◽  
Author(s):  
Donna Futterman ◽  
Karen Hein ◽  
Nancy Reuben ◽  
Ralph Dell ◽  
Nathan Shaffer

To address the unique manifestations of human immunodeficiency virus (HIV) among adolescents aged 13 through 21 years, a comprehensive evaluation and treatment program for high-risk and HIV-positive adolescents was developed in New York City in 1987. Among HIV-infected youth, mean age of testing was 18.2 years. One third of the HIV-positive patients were female and four fifths were African-American or Hispanic. No significant differences were found between HIV-positive (n = 50) and HIV-negative (n = 43) patients for age at first intercourse, injecting or other illicit drug use, history of sexually transmitted diseases, or survival sex (exchange of sex for money or drugs). HIV-positive males were more likely than HIV-negative males to have engaged in anal intercourse and to report a history of sexual abuse. Among infected females, 82% acquired HIV through heterosexual intercourse. Almost half (48%) of HIV-positive adolescents had significant immune dysfunction at the time of their initial visit (CD4 <500/mm3) and were eligible for zidovudine. Many HIV-positive adolescents continued high-risk behaviors such as intercourse without condoms, particularly those with ongoing dependence on drugs or alcohol. With the epidemic of HIV infection increasing nationwide among adolescents, specialized, comprehensive programs are needed to counsel and treat HIV-infected adolescents and youth in high-risk situations.

Author(s):  
Tawandra L Rowell-Cunsolo ◽  
Gloria Hu ◽  
Meghan Bellerose ◽  
Jianfang Liu

Abstract Background Due to the advent and success of antiretroviral therapy, the number of people living and aging with human immunodeficiency virus (HIV) has grown substantially. Although people living with HIV (PLHIV) are experiencing longer life expectancies, this achievement may be undermined by increasing and disproportionate chronic disease burden among PLHIV. Methods This study is a retrospective analysis of adult (≥18 years) inpatient hospital discharges from a large hospital system in the New York City, New York metropolitan area, between 1 January 2006 and 31 December 2016. We aimed to investigate (1) changes in the prevalence of Charlson-defined comorbidities among PLHIV hospitalized between 2006 and 2016 and (2) changes in the unadjusted prevalence ratio (PR) of comorbidities in HIV-positive versus HIV-negative admissions over time. Results Of 898 139 hospital admissions from 2006–2016, 19 039 (2.1%) were HIV positive. Across all admissions during the study period, the greatest comorbidity disparities between HIV-positive and HIV-negative admissions were mild liver disease (PR, 4.9 [95% confidence interval, 4.8–5.1]), moderate or severe liver disease (PR, 2.2 [2.0–2.4]), and chronic pulmonary disease (PR, 1.8 [1.8–1.8]). Conclusions The prevalence and relative burden of comorbidities among hospitalized PLHIV are changing over time. Careful monitoring and intensive discharge planning may be effective strategies for addressing the evolving health needs of PLHIV.


1989 ◽  
Vol 29 (3) ◽  
pp. 181-185 ◽  
Author(s):  
David M. Novick ◽  
Harold L. Trigg ◽  
Don C. Des Jarlais ◽  
Samuel R. Friedman ◽  
David Vlahov ◽  
...  

2020 ◽  
Vol 71 (11) ◽  
pp. 2933-2938 ◽  
Author(s):  
Keith Sigel ◽  
Talia Swartz ◽  
Eddye Golden ◽  
Ishan Paranjpe ◽  
Sulaiman Somani ◽  
...  

Abstract Background There are limited data regarding the clinical impact of coronavirus disease 2019 (COVID-19) on people living with human immunodeficiency virus (PLWH). In this study, we compared outcomes for PLWH with COVID-19 to a matched comparison group. Methods We identified 88 PLWH hospitalized with laboratory-confirmed COVID-19 in our hospital system in New York City between 12 March and 23 April 2020. We collected data on baseline clinical characteristics, laboratory values, HIV status, treatment, and outcomes from this group and matched comparators (1 PLWH to up to 5 patients by age, sex, race/ethnicity, and calendar week of infection). We compared clinical characteristics and outcomes (death, mechanical ventilation, hospital discharge) for these groups, as well as cumulative incidence of death by HIV status. Results Patients did not differ significantly by HIV status by age, sex, or race/ethnicity due to the matching algorithm. PLWH hospitalized with COVID-19 had high proportions of HIV virologic control on antiretroviral therapy. PLWH had greater proportions of smoking (P < .001) and comorbid illness than uninfected comparators. There was no difference in COVID-19 severity on admission by HIV status (P = .15). Poor outcomes for hospitalized PLWH were frequent but similar to proportions in comparators; 18% required mechanical ventilation and 21% died during follow-up (compared with 23% and 20%, respectively). There was similar cumulative incidence of death over time by HIV status (P = .94). Conclusions We found no differences in adverse outcomes associated with HIV infection for hospitalized COVID-19 patients compared with a demographically similar patient group.


1999 ◽  
Vol 94 (5, Part 1) ◽  
pp. 647-652
Author(s):  
MARGARET POLANECZKY ◽  
MICHELLE CADOGAN ◽  
KATHLEEN MCGUINNESS ◽  
MELISSA WATERSTONE

2006 ◽  
Vol 40 (5) ◽  
pp. 385-390 ◽  
Author(s):  
Allen Ahdoot ◽  
Donald P. Kotler ◽  
Jin S. Suh ◽  
Charles Kutler ◽  
Rachel Flamholz

Author(s):  
ELAINE J. ABRAMS ◽  
JEREMY WEEDON ◽  
JEANNE BERTOLLI ◽  
KATIE BORNSCHLEGEL ◽  
JOSEPH CERVIA ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document